Wells Fargo raises Xencor stock price target on kidney cancer data
Wells Fargo raises Xencor stock price target on kidney cancer data Investing.com
Covered in this story
Analyst targets on Wells Fargo
- Citi: $80.7 → $88 by Oct 2027 · Neutral via MarketBeat
- RBC Capital Markets: $79.9 → $92 by Oct 2027 · Outperform via TradingView
- TD Cowen: $81.6 → $95 by Oct 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $WFC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Wells Fargo →Dalsna Finance is currently tracking 51 stories mentioning Wells Fargo, the earliest published 20 Feb 2021.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.